Evidence map›Paper›PMID 41857185›Full record

ArticleScientific reports2026

Estimating major pathological response in non-small cell lung cancer patients with post-neoadjuvant therapy using MMT-net.

Chenghan Yang, Liqin Liu, Weijin Xiao, Feng Wu, Lei Guo, Chao Li

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Chenghan YangDepartment of Pathology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, 350014, China.
Liqin LiuThe School of Basic Medical Sciences, Fujian Medical University, Fuzhou, 350122, China.
Weijin XiaoDepartment of Pathology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, 350014, China.
Feng WuThe School of Basic Medical Sciences, Fujian Medical University, Fuzhou, 350122, China.
Lei GuoInterdisciplinary institute for Medical Engineering, Fuzhou University, Fuzhou, 350116, China. gankLei@fzu.edu.cn.
Chao LiDepartment of Pathology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, 350014, China. lichao3501@fjmu.edu.cn.

Funding

Joint Funds for the Innovation of Science and Technology, Fujian Province 2021Y9212National Natural Science Foundation of China 22404024Natural Science Foundation of Fujian Province 2021J01432
6 · The paper itself

Abstract

Neoadjuvant therapy (NAT) has demonstrated considerable effectiveness in treating locally advanced non-small cell lung cancer (NSCLC). Major pathological response (MPR), defined by the proportion of viable tumor cells in the tumor bed assessed through whole slide images (WSIs), is regarded as a crucial marker for predicting patient prognosis. While artificial intelligence (AI)-assisted WSI analysis has proven to be more effective than manual inspection, the intricate nature of analyzing post-NAT NSCLC WSIs still poses substantial clinical and computational challenges. In this study, we introduce a self-supervised learning model named the Multi-Magnifier Transformer Network (MMT-Net), designed for estimating MPR in NSCLC patients with post-NAT. The MMT-Net framework comprises three main components: a CNN backbone pretrained on unannotated pathological images for feature extraction, a multi-attention mechanism for fusing multi-scale features and a transformer layer for final classification. Validation results on the curated NSCLC post-NAT dataset have demonstrated that MMT-Net is more effective than commonly used methods for estimating MPR. Additionally, attention map visualizations show strong agreement with pathologist annotations, and the model outputs significantly correlate with immunohistochemistry markers such as CK and Ki67, confirming the reliability of MMT-Net. The proposed MMT-Net holds promise for improving the efficiency of MPR estimation, further advancing the clinical application of NAT in NSCLC.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsNeoadjuvant TherapyConvolutional Neural NetworksHumansDeep learningMajor pathological response estimationNeoadjuvant therapyWhole slide image analysis

Identifiers

PMID41857185
PMCPMC13136302

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.